



NDA 19-507/S-007

Sanofi-aventis, US, LLC
Attention: John Cook
55 Corporate Drive
PO Box 5925
Bridgewater, NJ 08807-0890

Dear Mr. Cook:

Please refer to your supplemental new drug application dated November 10, 2008, received November 12, 2008, submitted under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act for Kerlone (betaxolol hydrochloride) 10 mg and 20 mg Tablets

This “Changes Being Effected” supplemental new drug application provides for changes to the **WARNINGS**, **PRECAUTIONS**, **ADVERSE REACTIONS**, and **OVERDOSAGE** sections of the label as follows:

1. In **WARNINGS**, the sentence “Kerlone should not be given to patients with untreated pheochromocytoma” has been added after the seventh paragraph.
2. In **PRECAUTIONS/General**, the following sentence “The value of using beta-blockers in psoriatic patients should be carefully weighed since they have been reported to cause an aggravation in psoriasis” has been added as a second paragraph.
3. In **PRECAUTIONS/Information for patients**, the word “ophthalmologists” has been added to the fourth sentence of the third paragraph.
4. In **PRECAUTIONS/Drug Interactions**, the following sentences have been added as the sixth and seventh paragraphs respectively:

“Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta blockers”

“Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta blockers”

5. In **PRECAUTIONS/Pregnancy**, the sentence “Beta-blockers reduce placental perfusion, which may result in intrauterine fetal death, immature and premature deliveries. In addition, adverse effects (especially hypoglycemia and bradycardia) may occur in the fetus” has been added to the second paragraph.
6. In **PRECAUTIONS**, the following paragraph has been added:

“**Neonatal period:** The beta-blocker action persists in the neonate for several days after birth to a treated mother: there is an increased risk of cardiac and pulmonary complications in the neonate in the postnatal period. Bradycardia, respiratory distress and hypoglycemia have also been reported. Accordingly, attentive surveillance of the neonate (heart rate and blood glucose for the first 3 to 5 days of life) in a specialized setting is recommended.”

7. In **ADVERSE REACTIONS**, the words “(e.g., lupus erythematosus)” have been added to the second sentence of the fourth paragraph.
8. In **ADVERSE PEACTIONS/Potential adverse effects**, the following has been added as the fifth paragraph:

“Metabolic: Hypoglycemia.”

9. In **OVERDOSAGE/Bradycardia**, the following sentence “(see *Warnings: Anesthesia and major surgery*)” has been added to the second sentence of the first paragraph.

We have completed our review of this application, and it is approved, effective on the date of this letter, for use as recommended in the electronic labeling (SPL) submitted on November 10, 2008.

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call:

Lori Anne Wachter, RN, BSN
Regulatory Health Project Manager
(301) 796-3975

Sincerely,

{See appended electronic signature page}

Norman Stockbridge, M.D., Ph.D.
Director
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure: Approved labeling text

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Norman Stockbridge
5/12/2009 01:55:12 PM